United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - for restoration and maintenance of circulating blood volume where hypovolemia is demonstrated and colloid use is appropriate. when hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 20-25% albumin solutions should be used.1,2,3 acute liver failure is a special situation in which both hypovolemia and hypoalbuminemia can be present. albutein 25% can be used in such cases.1 albutein 25% may be of value in the treatment of shock or hypotension in renal dialysis patients.1 preoperative dilution of blood using albumin and crystalloid can be used in cardiopulmonary bypass procedures. albumin also may be used in the priming fluid.4,5,6 albutein 25% may be used to treat peripheral edema in patients with acute nephrosis who are refractory to cyclophosphamide, corticosteroid therapy or diuretics.1,2,7 albutein 25% may be indicated for subjects with hypoalbuminemia who are critically ill and/or actively bleeding. when albumin deficit is the result of excessive protein loss, the effect of albutein 25% administration will be temporary unless the underlying disorder is reversed.8,9,10 septic patients and patients undergoing major surgery may lose more than half of their circulating plasma volume.1,11 treatment with albutein 25% may be of value in such cases, especially when plasma colloid oncotic pressure is abnormally low.1 in the first 24 hours after thermal injury, large volumes of crystalloids are infused to restore the depleted extracellular fluid volume. beyond 24 hours, albutein 25% can be used to maintain plasma colloid osmotic pressure.2,12,13 protein loss from the third space due to infection (acute peritonitis, pancreatitis, mediastinitis or extensive cellulitis) may require treatment with an infusion of albumin.14,15 albutein 25% may be used as a plasma volume expander in fluid management relating to severe forms of ovarian hyperstimulation syndrome.16,17 albutein 25% is indicated for the treatment of neonatal hyperbilirubinemia. it may be used prior to or during an exchange procedure in an attempt to bind free bilirubin and enhance its excretion.18,19,20 albutein 25% infusions may be indicated in conjunction with diuretics to correct fluid overload and hypoproteinemia associated with ards.6,21 albutein 25% may be used to maintain cardiovascular function following removal of large volumes of ascitic fluid after paracentesis due to cirrhotic ascites.2,22,23,24 - hypersensitivity to albumin preparations or to any of the excipients. - severe anemia or cardiac failure with normal or increased intravascular volume.x risk summary there is no data with albutein 25% use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with albutein 25%. it is not known whether albutein 25% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. albutein 25% should be given to a pregnant woman only if clearly needed. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the presence of albutein 25% in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for albutein 25% and any potential adverse effects on the breastfed infant from albutein 25%.     no human or animal data. use only if clearly needed. no human or animal data. use only if clearly needed.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - for restoration and maintenance of circulating blood volume where hypovolemia is demonstrated and colloid use is appropriate. when hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 20-25% albumin solutions should be used.1,2,3 acute liver failure is a special situation in which both hypovolemia and hypoalbuminemia can be present. albutein 5% can be used in such cases.1 albutein 5% may be of value in the treatment of shock or hypotension in renal dialysis patients.1 preoperative dilution of blood using albumin and crystalloid can be used in cardiopulmonary bypass procedures. albumin also may be used in the priming fluid.4,5,6 albutein 5% may be indicated for subjects with hypoalbuminemia who are critically ill and/or actively bleeding. when albumin deficit is the result of excessive protein loss, the effect of albutein 5% administration will be temporary unless the underlying disorder is reversed.7,8,9 septic patients and patients undergoing major surgery may

United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - for restoration and maintenance of circulating blood volume where hypovolemia is demonstrated and colloid use is appropriate. when hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 20-25% albumin solutions should be used.1,2,3 acute liver failure is a special situation in which both hypovolemia and hypoalbuminemia can be present. albutein 20% can be used in such cases.1 albutein 20% may be of value in the treatment of shock or hypotension in renal dialysis patients.1 preoperative dilution of blood using albumin and crystalloid can be used in cardiopulmonary bypass procedures. albumin also may be used in the priming fluid.4,5,6 albutein 20% may be used to treat peripheral edema in patients with acute nephrosis who are refractory to cyclophosphamide, corticosteroid therapy or diuretics.1,2,7 albutein 20% may be indicated for subjects with hypoalbuminemia who are critically ill and/or actively bleeding. when albumin deficit is the result of excessive protein loss, the effect of albutein 20% administration will be temporary unless the underlying disorder is reversed.8,9,10  septic patients and patients undergoing major surgery may lose more than half of their circulating plasma volume.1,11 treatment with albutein 20% may be of value in such cases, especially when plasma colloid oncotic pressure is abnormally low.1   in the first 24 hours after thermal injury, large volumes of crystalloids are infused to restore the depleted extracellular fluid volume. beyond 24 hours, albutein 20% can be used to maintain plasma colloid osmotic pressure.2,12,13  protein loss from the third space due to infection (acute peritonitis, pancreatitis, mediastinitis or extensive cellulitis) may require treatment with an infusion of albumin.14,15 albutein 20% may be used as a plasma volume expander in fluid management relating to severe forms of ovarian hyperstimulation syndrome.16,17 albutein 20% is indicated for the treatment of neonatal hyperbilirubinemia. it may be used prior to or during an exchange procedure in an attempt to bind free bilirubin and enhance its excretion.18,19,20 albutein 20% infusions may be indicated in conjunction with diuretics to correct fluid overload and hypoproteinemia associated with ards.6,21 albutein 20% may be used to maintain cardiovascular function following removal of large volumes of ascitic fluid after paracentesis due to cirrhotic ascites.2,22,23,24 - hypersensitivity to albumin preparations or to any of the excipients. - severe anemia or cardiac failure with normal or increased intravascular volume. risk summary   there is no data with albutein 20% use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with albutein 20%. it is not known whether albutein 20% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. albutein 20% should be given to a pregnant woman only if clearly needed. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the presence of albutein 20% in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for albutein 20% and any potential adverse effects on the breastfed infant from albutein 20%. no human or animal data.  use only if clearly needed.  no human or animal data.  use only if clearly needed. 

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma limited - albumin human - solution for infusion - 200 g/l

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma limited - albumin human - solution for infusion - 50 g/l

Malta - English - Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - albumin, human - solution for infusion - albumin, human 4.5 percent weight/volume - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - albumin, human - solution for infusion - albumin, human 20 percent weight/volume - blood substitutes and perfusion solutions

United States - English - NLM (National Library of Medicine)

iso-tex diagnostics, inc. - human serum albumin i-131 (unii: ach35131l1) (human serum albumin i-131 - unii:ach35131l1) - iodinated i-131 serum albumin 0.025 mci in 1 ml - volumex (iodinated i 131 allbumin injection) is indicated for use in determinations of total blood and plasma volumes and in protein turnover studies none known.

Malta - English - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - albumin, human - solution for infusion - albumin, human 50 g/l - blood substitutes and perfusion solutions

United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - emergency treatment of hypovolemic shock plasbumin-20 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (plasbumin® -5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual; i.e., about 2 g per kg body weight in the absence of active bleeding. although plasbumin-5 is to be preferred for the usual volume deficits, plasbumin-20 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic flu